Sunday, April 12, 2020

Cyient Contributes to Telangana Chief Minister’s Relief Fund to Fight COVID-19

Cyient, a global engineering and technology solutions company, today announced today that it has contributed Rupees Two Crore to the Telangana Chief Minister’s Relief Fund to support the government’s efforts in fighting the Covid-19 pandemic. Cyient’s contribution includes donations from several of its India based employees.  

Krishna Bodanapu, Cyient’s Managing Director & CEO handed over the contribution to Telangana Chief Minister Shri K. Chandrashekar Rao on 11 April in the presence of Shri Etela Rajendra, Minister Medical & Health and Family Welfare and BVR Mohan Reddy, Cyient’s Founder & Executive Chairman.

BVR Mohan Reddy, Cyient’s Founder & Executive Chairman commented, “In the face of this devastating health crisis, Cyient feels even more responsible towards the communities that sustain us and we are keen to extend our resources and technology capabilities to support the Telangana Government. We are proud of the government’s firm and decisive actions to contain the Covid-19 pandemic and greatly appreciate their pragmatic efforts to support business continuity during these unprecedented times.” 

About Cyient:
Cyient (Estd: 1991, NSE: CYIENT) is a global engineering and technology solutions company.  As a Design, Build, and Maintain partner for leading organizations worldwide, Cyient takes solution ownership across the value chain to help customers focus on their core, innovate, and stay ahead of the curve. The company leverages digital technologies, advanced analytics capabilities, and its domain knowledge and technical expertise, to solve complex business problems.
With over 15,000 employees globally, Cyient partners with customers to operate as part of their extended team in ways that best suit their organization’s culture and requirements. Cyient’s industry focus includes aerospace and defense, healthcare, telecommunications, rail transportation, semiconductor, geospatial, industrial, and energy.
For more information, please visit
Follow news about the company at @Cyient.

No comments: